All News
Abs#0501 @RheumNow #ACR23
Uveitis in SpA, from Greece
AxSpA: 11.7% Uveitis. RF: HLA-B27 (OR 4.15), periperhal arthritis (OR 3.05)
PsA: 2.7% Uveitis. Ass w/ SpA FHx, Axial dis at dx, disease duration
Permanent vision loss in 16% AxSpA, 30% PsA pts, all with recurrent uveitis
Eric Dein ( View Tweet)
EISER study: Undiagnosed IBD in SpA
Abs#0495 #ACR23 @RheumNow
559 pts, 47% PsA/53% SpA (80% r-AxSpA)
Higher mean fecal calprotectin in r-AxSpA (395 vs 305 nrAxSpA/PsA)
14.6% IBD symptoms, 23 patients (4.4% were dx w IBD)
Fecal calprotectin & history can uncover IBD
#ACRBest
Eric Dein ( View Tweet)
#ACR23 Please find my preview article on selected #SLE abstracts to be presented at year’s conference - towards Glucocorticoid-Free zone in lupus @RheumNow
https://t.co/1kM7LWc64V https://t.co/WK9X7UpsNi
Md Yuzaiful Md Yusof ( View Tweet)
High hs-CRP predicts PsO -> PsA?
Abs#0484 #ACR23 @RheumNow
589 PsO pts wo PsA, followed mean 7.5 years
57 pts developed PsA (1.2 events/yr)
Higher levels of b/l hs-CRP seen w: arthrlalgia, obesity, females
Higher hs-CRP ass. w/ PsA - p=0.002, but HR only 1.03 (CI 1.01-1.05)
Eric Dein ( View Tweet)
Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/vucBYeM1P5 https://t.co/YqdqZWFhfd
Dr. John Cush RheumNow ( View Tweet)
In young patients who have a spinal MRI, lesions are reported in most patients, and similar in males:females. SIJ MRI findings are reported in one out of three patients, being more frequently in males @DiegoBenavent Abst #160 #ACR23 @RheumNow https://t.co/aF9WnP7jpY https://t.co/E9UuZ0sWZm
Dr. Antoni Chan ( View Tweet)
#Benefits of #hudroxychloroquine - reduced lipids, clots, CV events, infection AND now improved #fatty #liver #NAFLD….@RheumNow #ACR23 @ACRheum https://t.co/Y43JETY6F3
Janet Pope ( View Tweet)
Sarilumab for relapsing of PMR. Any thing to to taper off prednisone quickly.
#ACR23 , year in review.
Lost of good studies and smart discussions @RheumNow at Make rheum for PMR month. https://t.co/VyRP8ls3OC
Nouf Al hemmadi ( View Tweet)
Thank you @synovialjoints @RheumNow for highlighting our work
#ACR23 #ACRambassador
@ACRheum
@ArLARheumatolog
#ARCH_ArLAR https://t.co/rphaODphD1
Nelly ZIADE 🍀 Nellziade ( View Tweet)
If successful you may need how to pronounce these emerging therapeutics in #inflammatory #arthritis @RheumNow #ACR23 @ACRheum https://t.co/aOogwQCsCM
Janet Pope ( View Tweet)
One for you, one for me!
So many pasalubong char
@RHEUMarampa
@RheumNow
#acr23 #ACRambassador https://t.co/v0mZ9vbadx
Lisa 🐳🗺🧭 rheumarhyme ( View Tweet)
Cellular based biology explanation of sex bias in ARDs 👀
Data from AMP w/ sc-RNA seq from synovial tissue shows:
Enriched inflammatory pathways in females synovial macrophages clusters vs. males
Basis for gender specific treatment strategies?
@RheumNow ABST0724 #ACR23 https://t.co/1p8PDIRNoI
Aurelie Najm ( View Tweet)
Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels?
Radiographic progression equally low in both drugs
NO difference in syndesmophytes or CRP
@RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE
Robert B Chao, MD ( View Tweet)
In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH
✳️TRAF5 deficiency activates BMP/TGFB signaling w/⬆️PAEC apoptosis
✳️TRAF5 overexpression attenuated PAH sxs in mice
TRAF5 as potential BM for dx/novel tx target in SLE-PAH?
#ACR23 ABST0723 @RheumNow https://t.co/WT9vQo8y8s
sheila ( View Tweet)
Important plenary re:reduced vs standard GC for AAV... IRL
PEXIVAS & recent guidelines supported low dose taper
Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts
Need full data but yikes...
@RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok
Mike Putman EBRheum ( View Tweet)
Abst#0725 #ACR23 @RheumNow
PEXIVAS Real life data!
GPA & MPA pts - Retrosp observ study
⭐️Reduced-dose GC regimen ass w/ INCREASED risk of death, ESKD, progression
Greatest risk: pt w Cr levels >300 umol/L, RTX induction Rx
⚠️Caution w/ reduced GC, RTX, severe kidney dis
#ACRBest https://t.co/7qI5c1ZiqO
Eric Dein ( View Tweet)
Look who I interviewed for @RheumNow!!@ashira_md shares the story of APOL1 effects on SLE . Patients with the variants have more aggressive renal and vascular disease. #DuboisLecture #ACR23 #StrongWomen #FutureNobelRecipient https://t.co/IzRsHwaMIb
TheDaoIndex KDAO2011 ( View Tweet)
Interesting study on PEXIVAS reduced steroid use from today's plenary session!
Reduced steroid dose in GPA/MPA pts associated w/
INCREASED risk of death, ESKD, progression of dz
Even greater risk in pts with higher Cr lvls or RTX induction use
@RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf
Robert B Chao, MD ( View Tweet)
In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67-0.83) but no diff bet BEL vs. MTX/AZA at 3yrs
Further prospective studies req'd?
BEL remains an option for non-renal SLE tx.
#ACR23 ABST0606 @RheumNow https://t.co/KabBeXKpvk
sheila ( View Tweet)
Did you know?
👉APOL1 variants are protective against trypanosomiasis.
👉Despite reassuring renal biopsies, SLE pts with #APOL1 variants had:
⬆️progression to ESRD, ⬆️atherosclerosis, ⬆️osteonecrosis (likely related to endothel dysfnx) #ACR23 @ashira_md @RheumNow #DuboisLecture https://t.co/w1lnGMPFAQ
TheDaoIndex KDAO2011 ( View Tweet)